Circulating and adipose lipid metabolism
prednisolone-induced
AZD4017 treatment prevented the prednisolone-induced increase in basal circulating triacylglycerol (TAG) levels. Furthermore, across all the phases of the 2-step hyperinsulinaemic euglycaemic clamp, the changes in circulating TAG levels associated with prednisone administration, were significantly reduced by AZD4017 (Supplementary Table 